Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, UVB irradiation increased mast cell degranulation only when skin was innervated, suggesting that the interaction between mast cells and nerve fibres may exacerbate solar elastosis by promoting dysfunctional dermal elastic fiber accumulation, but further research is needed for confirmation.

This study found that apremilast treatment did not result in sustained improvement for most patients with treatment-resistant alopecia areata, although one patient experienced significant benefit.

Daylight photodynamic therapy is effective and well-tolerated for treating actinic keratoses with minimal side effects.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study found that cetirizine-loaded niosomal gels demonstrated superior skin deposition and retention compared to plain cetirizine gel, suggesting potential for improved topical management of alopecia.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

This study suggests that combining topical squaric acid dibutylester with other therapies may improve hair regrowth in patients with alopecia areata unresponsive to topical therapy alone.

In this study, simvastatin/ezetimibe treatment led to partial hair regrowth in about 29% of patients with recalcitrant alopecia areata, suggesting it may be a viable alternative therapy for this condition.

This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

This case report details a 45-year-old woman with SLE who experienced severe leukopenia and hair loss attributed to azathioprine, suggesting the importance of recognizing these potential adverse effects for timely intervention.

This abstract provides no new clinical results; it discusses the role of surgery and interventional radiotherapy in treating cutaneous squamous cell carcinoma.

In this study, adults with persistent facial erythema of rosacea showed significantly greater improvement when treated with once-daily oxymetazoline cream compared to a vehicle, and using baseline photographs in assessments enhanced the accuracy by reducing perceived vehicle effects.

The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This study highlights that azelaic acid, initially recognized for skin hypopigmentation, shows potential in treating various skin conditions due to its complex mechanisms, even though these are not yet fully understood, indicating a need for further research.

In this case report, a 47-year-old man with extensive psoriasis saw significant improvement in scaling and itching after using a new lotion containing clobetasol and other ingredients for one week, but further research is needed to confirm these findings.

This review explores the synthesis and potential of azasteroids as novel drugs, discussing challenges in their production and reporting no new clinical results.

This study synthesized a new organic sunscreen with broad photoprotective properties and demonstrated it to be non-toxic. The resultant cream, containing nanostructured lipid carriers, showed suitable application qualities and achieved a satisfactory SPF value of 16.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

This study found that inhibiting the ATR kinase with VE-822 impairs DNA repair capability in quiescent human keratinocytes exposed to solar-simulated UV radiation, suggesting ATR's critical role in facilitating effective DNA damage repair and cellular recovery under UV stress conditions.

This study found that a combination of low-dose isotretinoin and oral azithromycin pulse effectively treats severe acne with an acceptable side effect profile and relatively low relapse rates.

Alpha-hydroxy acids, like glycolic acid, safely improve skin issues and work on all skin types.

This clinical trial found that Sandalore® 1% significantly reduced hair shedding and increased hair volume and anagen hair follicles in women with telogen effluvium compared to placebo.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.